Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it made further steps towards centralized current good manufacturing practice (“cGMP”) manufacturing of its lead drug candidate Iomab™-B. Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) shares after opening at $11.26 moved to $11.26 on last trade day and at the end of the day closed at $10.30. Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) showed a negative weekly performance of -13.81%.
Flamel Technologies (NASDAQ:FLML) will release financial results for the first quarter of fiscal year 2014 on Monday, May 12, 2014, before the market open. A conference call to discuss these results has been scheduled for Monday, May 12th at 10:00 a.m. ET. A question and answer period will follow management’s prepared remarks. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) shares fell -5.55% in last trading session and ended the day on $11.58. FLML return on equity ratio is recorded as -584.30% and its return on assets is -32.80%. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) yearly performance is 122.26%.
Biota Pharmaceuticals Inc. (NASDAQ:BOTA) for the first quarter of 2014, expects to record worldwide Testim revenues of approximately $11 to 13 million, compared to $45.5 million in the first quarter of 2013. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) shares moved down -7.52% in last trading session and was closed at $3.32, while trading in range of $3.25 – $3.50. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) year to date (YTD) performance is -20.76%.
GenMark Diagnostics (NASDAQ:GNMK) is set to post its Q114 quarterly earnings results on Tuesday, May 6th. Analysts expect GenMark Diagnostics to post earnings of ($0.25) per share and revenue of $6.40 million for the quarter.GenMark Diagnostics, Inc. (NASDAQ:GNMK) weekly performance is 1.03%. On last trading day company shares ended up $8.80. GenMark Diagnostics, Inc. (NASDAQ:GNMK) distance from 50-day simple moving average (SMA50) is -17.19%. Analysts mean target price for the company is $16.20.